IL6 and rheumatoid arthritis: In that respect, the development of tocilizumab, a monoclonal antibody which inhibits the interaction between IL-6 and the various forms of the IL-6 receptor, was the perceived underlying mechanism for neutralizing IL-6 activation of the JAK/STAT signaling pathway in RA [17,18,19,20].